Literature DB >> 25755168

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.

Judith Weiland1,2, Alex Elder1, Victoria Forster1, Olaf Heidenreich1, Steffen Koschmieder3, Josef Vormoor1,4.   

Abstract

Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BCP-ALL; CD19; blinatumomab; childhood leukemia; pre-BCR

Mesh：

Substances：

Year:  2015        PMID： 25755168     DOI： 10.1002/pbc.25462

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  12 in total

Review 1.  Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.

Authors:  Shang Mengxuan; Zhou Fen; Jin Runming
Journal:  Front Pediatr       Date:  2022-06-23       Impact factor: 3.569

Review 2.  Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Authors:  Aharon Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 3.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 4.  The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Authors:  J Eswaran; P Sinclair; O Heidenreich; J Irving; L J Russell; A Hall; D P Calado; C J Harrison; J Vormoor
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

Review 5.  Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera; Albert Ferrer; Jordi Ribera; Eulàlia Genescà
Journal:  Onco Targets Ther       Date:  2015-06-24       Impact factor: 4.147

6.  BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.

Authors:  J Weiland; D Pal; M Case; J Irving; F Ponthan; S Koschmieder; O Heidenreich; A von Stackelberg; C Eckert; J Vormoor; A Elder
Journal:  Leukemia       Date:  2016-03-17       Impact factor: 11.528

7.  CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Authors:  Annette Romanski; Christoph Uherek; Gesine Bug; Erhard Seifried; Hans Klingemann; Winfried S Wels; Oliver G Ottmann; Torsten Tonn
Journal:  J Cell Mol Med       Date:  2016-03-23       Impact factor: 5.310

8.  Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Authors:  Jean-Marc Hoffmann; Maria-Luisa Schubert; Lei Wang; Angela Hückelhoven; Leopold Sellner; Sophia Stock; Anita Schmitt; Christian Kleist; Ulrike Gern; Angelica Loskog; Patrick Wuchter; Susanne Hofmann; Anthony D Ho; Carsten Müller-Tidow; Peter Dreger; Michael Schmitt
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

9.  CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.

Authors:  Christian B Schiller; Todd A Braciak; Nadja C Fenn; Ursula J E Seidel; Claudia C Roskopf; Sarah Wildenhain; Annemarie Honegger; Ingo A Schubert; Alexandra Schele; Kerstin Lämmermann; Georg H Fey; Uwe Jacob; Peter Lang; Karl-Peter Hopfner; Fuat S Oduncu
Journal:  Oncotarget       Date:  2016-12-13

10.  Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy.

Authors:  Yung-Che Chen; An-Shen Lin; Yu-Chiang Hung; Kuang-Den Chen; Ching-Yuan Wu; Chien-Hao Lie; Chang-Chun Hsiao; Chung-Jen Chen; Shih-Feng Liu; Wen-Feng Fang; Jen-Chieh Chang; Ting-Ya Wang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Sum-Yee Leung; Mao-Chang Su; Meng-Chih Lin
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.